Anavex Life Sciences Corp (AVXL)

[TTTav66]

From Ariana Pharma: https://www.arianapharma.com/anavex-ad-pd-2022-international-conference/

Anavex Life Sciences and Ariana Pharma present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Ariana, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.

Cambridge, Mass. and Paris, France, March 23rd, 2022. Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference.

MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant, corresponding to a relative improvement of 18.9% over 14 weeks. Balanced and global improvements were observed within all MDS-UPDRS sub-scores Part I-IV.

SIGMAR1 mRNA expression biomarker, previously identified using Ariana’s eXplainable Artificial Intelligence (xAI) KEM® technology, was significantly increased in ANAVEX®2-73 treated patients vs. placebo over the course of treatment (p=0.035). In addition, this biomarker was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system.

This finding builds on the KEM® AI-driven precision medicine clinical development platform of ANAVEX®2-73, where the SIGMAR1 mRNA expression biomarker as previously identified as a potential biomarker (Hampel et al, Alzheimer Dement (N Y). 2020; 6(1): e12013) is characterized across multiple indications, including Alzheimer’s Disease and Rett syndrome.

“The reported strong positive biomarker and clinical results in Parkinson’s Disease Dementia, building on previously reported positive results in RETT syndrome and Alzheimer’s disease, further illustrate the power of KEM® Explainable AI to accelerate precision medicine drug development building on in-depth understanding of the intersection between SIGMAR1 molecular pathways and disease biology” said Mohammad Afshar, M.D., Ph.D., Chief Executive Officer of Ariana Pharma.